eligibility_summary
Key eligibility: ECOG 0–1, life expectancy ≥12 wks, ≥3 prior therapies (PI, IMiD, anti‑CD38), progressive disease or intolerance to last therapy, measurable disease, contraception. Exclude: recent anti‑cancer tx (<3 wks), auto‑SCT <100 d, any prior allo‑SCT/solid organ tx, HLH/MAS, autoimmune or CNS disease/MM, major CV or liver disease, O2‑dependent lung disease, active infection or IV COVID tx within 14 d, other protocol criteria apply.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase Ib study in relapsed/refractory multiple myeloma tests: 1) Cevostamab (RO7187797), an IgG-based CD3×FcRH5 bispecific T-cell engager that binds FcRH5 on myeloma plasma cells and CD3 on T cells to redirect cytotoxic T-cell killing. 2) XmAb24306 (RO7310729), an engineered, long-acting IL-15/IL-15Rα Fc cytokine agonist designed to expand and activate CD8+ T cells and NK cells via IL-2/15Rβγ–JAK/STAT signaling. Arm A: combination dose-escalation/expansion, Arm B: single-agent cevostamab. Tocilizumab (anti–IL-6R mAb) may be used for CRS. Targets/pathways: FcRH5 on malignant plasma cells, CD3/TCR activation on T cells, IL-15 signaling to expand effector T/NK cells, IL-6 pathway blockade for CRS mitigation.